Shares of Nymox Pharmaceutical (NYMX) spiked more than 70% to $1.74 in early trading Monday after the company announced long-term clinical trial results from the company’s NX-1207 Phase 2 prostate cancer study NX03-0040. Nymox said the new results demonstrate statistically significant (p=.0067) better outcomes at up to 2.8 years for NX-1207 treated patients compared to controls. Trial participants included 146 patients with low grade localized prostate cancer at 44 U.S. investigational sites.
Paul Averback MD, CEO of Nymox said in a statement, “These new results show the potential of NX-1207 to offer men with the most common form of low-grade prostate cancer a significant tangible benefit in terms of avoidance of radiation and/or surgery and the related risks, discomforts, and permanent side effects. The results show a significant positive effect from a single painless injection which is very exciting.”
Approximately 6.4 million NYMX shares have already changed hands, compared to the stock’s average daily volume of 1.69 million. Shares up down 67% year-over-year ; up 307% year-to-date.